Clinical trial
A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer
NCT00323479 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer
- Lead sponsor
- AstraZeneca
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- January 31, 2009
- Enrollment
- 114 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
early breast cancer